REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$7.85 USD
-0.05 (-0.63%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $7.85 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth A Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, REGENXBIO Inc. has a market cap of $396.27M, which represents its share price of $7.90 multiplied by its outstanding shares number of 50.16M. As a small-cap company, RGNX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RGNX 7.85 -0.05(-0.63%)
Will RGNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RGNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGNX
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
RGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Other News for RGNX
Barclays Lowers Price Target for Regenxbio (RGNX) to $37.00 | RGNX Stock News
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript
RGNX: Chardan Capital Maintains Buy Rating with $52 Target | RGNX Stock News
Regenxbio price target lowered by $4 at RBC Capital, here's why